The road ahead: emerging therapies for primary IgA nephropathy
Primary IgA nephropathy (IgAN) is the most common form of primary glomerulopathy. A slowly progressive disease presenting in the young to middle-aged, most patients with reduced eGFR or proteinuria will progress to end-stage kidney disease (ESKD) in their lifetimes. The pathogenesis involves increas...
Saved in:
Main Authors: | Edward J. Filippone, Rakesh Gulati, John L. Farber |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Nephrology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneph.2025.1545329/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancing the application of the analytical renal pathology system in allograft IgA nephropathy patients
by: Xumeng Liu, et al.
Published: (2024-12-01) -
The transcription factor HMGB2 indirectly regulates APRIL expression and Gd-IgA1 production in patients with IgA nephropathy
by: Huijuan Tian, et al.
Published: (2024-12-01) -
Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials
by: Ying Liu, et al.
Published: (2025-01-01) -
Clinical features, pathological characteristics, and prognosis of patients with IgA nephropathy complicated with nephrotic syndrome
by: Li Tan, et al.
Published: (2025-01-01) -
Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
by: Michele Maremmani, et al.
Published: (2025-01-01)